Ly2127399 (DrugBank: -)
3 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 9 |
| 46 | 悪性関節リウマチ | 50 |
| 49 | 全身性エリテマトーデス | 21 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-007459-28-BG (EUCTR) | 30/04/2010 | 29/04/2010 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 14.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 245 | France;Czech Republic;Hungary;Finland;Belgium;Denmark;Bulgaria;Germany | |||
| 2 | EUCTR2008-007459-28-DE (EUCTR) | 08/10/2009 | 23/12/2008 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 245 | France;Czech Republic;Hungary;Finland;Belgium;Denmark;Bulgaria;Germany | |||
| 3 | EUCTR2008-007459-28-BE (EUCTR) | 21/09/2009 | 07/01/2009 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 500 | France;Czech Republic;Hungary;Finland;Belgium;Denmark;Bulgaria;Germany | |||
| 4 | EUCTR2008-007459-28-CZ (EUCTR) | 22/07/2009 | 05/05/2009 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 245 | Hungary;Finland;Germany;Czech Republic;Denmark;Belgium;Bulgaria;France | |||
| 5 | EUCTR2008-007459-28-DK (EUCTR) | 09/07/2009 | 29/05/2009 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 245 | France;Czech Republic;Hungary;Finland;Belgium;Denmark;Bulgaria;Germany | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2008-007459-28-HU (EUCTR) | 01/07/2009 | 27/04/2009 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 500 | Finland;Hungary;Czech Republic;Germany;Denmark;Belgium;Bulgaria;France | |||
| 7 | EUCTR2008-007459-28-FR (EUCTR) | 01/07/2009 | 15/05/2009 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 500 | Hungary;Finland;Czech Republic;Germany;Denmark;Belgium;Bulgaria;France | |||
| 8 | EUCTR2008-007459-28-FI (EUCTR) | 25/06/2009 | 18/03/2009 | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: N/a Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 245 | France;Czech Republic;Hungary;Finland;Belgium;Denmark;Bulgaria;Germany | |||
| 9 | NCT00882999 (ClinicalTrials.gov) | April 2009 | 16/4/2009 | A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) | Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: LY2127399;Drug: Placebo | Eli Lilly and Company | NULL | Completed | 18 Years | 64 Years | All | 245 | Phase 2 | United States;Bulgaria;Czechia;France;Germany;Hungary;Israel;Poland;Romania;Russian Federation;Serbia;Slovakia;Ukraine;Belgium;Canada;Czech Republic;Denmark;Finland;Switzerland |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-001618-40-PL (EUCTR) | 04/01/2013 | 31/10/2012 | Evaluation of the blood concentration of Tabalumab after the administration of Tabalumab using prefilled syringe or auto-injector in patients with Rheumathoid Arthritis that have not responded correctly to treatment with Methotrexate. | Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate. | Rheumatoid Arthritis MedDRA version: 14.1;Level: LLT;Classification code 10042952;Term: Systemic rheumatoid arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: tabalumab Product Code: LY2127399 Other descriptive name: TABALUMAB | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 180 | United States;Czech Republic;Argentina;Poland;Russian Federation | |||
| 2 | EUCTR2012-001618-40-CZ (EUCTR) | 05/11/2012 | 03/08/2012 | Evaluation of the blood concentration of Tabalumab after the administration of Tabalumab using prefilled syringe or auto-injector in patients with Rheumathoid Arthritis that have not responded correctly to treatment with Methotrexate. | Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled syringe or Auto-Injector in Patients with Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate. | Rheumatoid Arthritis MedDRA version: 14.1;Level: LLT;Classification code 10042952;Term: Systemic rheumatoid arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: tabalumab Product Code: LY2127399 Other descriptive name: TABALUMAB | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 180 | United States;Czech Republic;Argentina;Poland;Russian Federation | |||
| 3 | NCT01576549 (ClinicalTrials.gov) | May 2012 | 10/4/2012 | A Study of LY2127399 in Rheumatoid Arthritis | An Exploratory Open-Label Biomarker Study of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Synovial Biopsies | Rheumatoid Arthritis | Drug: LY2127399 | Eli Lilly and Company | NULL | Terminated | 18 Years | N/A | All | 2 | Phase 2 | United States |
| 4 | EUCTR2010-022208-36-PL (EUCTR) | 05/12/2011 | 08/04/2011 | An Open Label Study for Patients With Rheumatoid Arthritis (FLEX-P) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) (FLEX-P) | Rheumatoid Arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1505 | Phase 3b | Germany;Malaysia;France;Bulgaria;Brazil;Australia;South Africa;New Zealand;Peru;Korea, Republic of;United States;Greece;Croatia;Poland;Hungary;Colombia;Italy;Lithuania;India;Russian Federation;Slovakia;Ukraine;Taiwan;Sri Lanka;Argentina;Mexico;Romania;Spain;Japan | ||
| 5 | EUCTR2010-022206-40-PL (EUCTR) | 26/07/2011 | 11/04/2011 | A Rheumatoid Arthritis Study in Patients (FLEX-O) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX-O) | Rheumatoid Arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: n/a Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: n/a | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1002 | Phase 3 | United States;Taiwan;Slovakia;Ukraine;Lithuania;Russian Federation;Colombia;Sri Lanka;India;Hungary;Mexico;Argentina;Poland;Malaysia;Romania;Croatia;Peru;Australia;South Africa;Bulgaria;New Zealand;Japan;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2010-022207-22-PL (EUCTR) | 22/07/2011 | 11/04/2011 | A Study in Patients With Rheumatoid Arthritis(FLEX-V) | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors (FLEX-V) | Rheumatoid Arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: n/a Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: n/a | Eli Lilly and Company | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 555 | Phase 3 | Germany;Colombia;Malaysia;Italy;Australia;Brazil;Russian Federation;New Zealand;Argentina;Mexico;Taiwan;Korea, Republic of;Spain;Japan;Greece;United States;Poland | ||
| 7 | EUCTR2010-022205-17-PL (EUCTR) | 19/07/2011 | 08/04/2011 | A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate (FLEX-M) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy(FLEX-M) | Rheumatoid Arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: n/a Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: n/a Trade Name: Boostrix® Product Name: Boostrix® Product Code: - Other descriptive name: DIPHTHERIA TOXOID Other descriptive name: TETANUS TOXOID Other descriptive name: PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE Other descriptive name: PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE Trade Name: PNEUMOVAX® 23 Product Name: PNEUMOVAX® 23 Product Code: - Other descriptive name: pneumococcal serotypes | Eli Lilly and Company | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 990 | Phase 3 | Hungary;Colombia;Malaysia;Bulgaria;South Africa;Australia;Brazil;Lithuania;India;Slovakia;Russian Federation;Ukraine;New Zealand;Peru;Taiwan;Sri Lanka;Mexico;Argentina;Romania;Korea, Republic of;Japan;United States;Croatia;Poland | ||
| 8 | EUCTR2010-022208-36-GR (EUCTR) | 21/06/2011 | 16/05/2011 | An Open Label Study for Patients With Rheumatoid Arthritis | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | Rheumatoid Arthritis MedDRA version: 13.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1505 | Phase 3b | United States;Taiwan;Greece;Spain;Ukraine;Russian Federation;Colombia;Sri Lanka;Italy;India;Malaysia;Australia;Peru;South Africa;Korea, Republic of;Lithuania;Hungary;Mexico;Argentina;Poland;Brazil;Croatia;Bulgaria;Germany;New Zealand;Japan | ||
| 9 | EUCTR2010-022207-22-DE (EUCTR) | 08/06/2011 | 03/12/2010 | A Study in Patients With Rheumatoid Arthritis (FLEX-V) | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors (FLEX-V) | Rheumatoid Arthritis MedDRA version: 14.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: not available Other descriptive name: not available Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: not available Other descriptive name: not available | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 555 | Phase 3 | United States;Taiwan;Greece;Spain;Russian Federation;Colombia;Italy;Mexico;Argentina;Poland;Brazil;Malaysia;Australia;Germany;New Zealand;Japan;Korea, Republic of | ||
| 10 | EUCTR2010-022208-36-DE (EUCTR) | 08/06/2011 | 03/12/2010 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | Rheumatoid Arthritis MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1505 | Phase 3b | Hungary;Greece;Poland;Spain;Lithuania;Bulgaria;Germany;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01215942 (ClinicalTrials.gov) | June 2011 | 5/10/2010 | An Open Label Study for Participants With Rheumatoid Arthritis | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) | Rheumatoid Arthritis | Drug: LY2127399 | Eli Lilly and Company | NULL | Terminated | 18 Years | N/A | All | 1086 | Phase 3 | United States;Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;France;Germany;Greece;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Sri Lanka;Taiwan;Ukraine;Italy;Peru |
| 12 | EUCTR2010-022206-40-LT (EUCTR) | 01/04/2011 | 28/12/2010 | A Rheumatoid Arthritis Study in Patients(FLEX-O) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX-O) | Rheumatoid Arthritis MedDRA version: 14.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: not available Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1002 | Phase 3 | United States;Taiwan;Slovakia;Ukraine;Lithuania;Russian Federation;Colombia;Sri Lanka;India;Hungary;Mexico;Argentina;Poland;Malaysia;Romania;Croatia;Australia;Peru;South Africa;Bulgaria;Japan;New Zealand | ||
| 13 | EUCTR2010-022205-17-LT (EUCTR) | 01/04/2011 | 28/12/2010 | A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate(FLEX-M) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy (FLEX-M) | Rheumatoid Arthritis MedDRA version: 14.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Other descriptive name: Not available | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 990 | Phase 3 | United States;Taiwan;Slovakia;Ukraine;Lithuania;Russian Federation;Colombia;Sri Lanka;India;Hungary;Mexico;Argentina;Malaysia;Brazil;Poland;Croatia;Romania;Australia;Peru;Bulgaria;South Africa;Japan;New Zealand;Korea, Republic of | ||
| 14 | EUCTR2010-022208-36-LT (EUCTR) | 01/04/2011 | 28/12/2010 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | Rheumatoid Arthritis MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1505 | Phase 3b | Hungary;Greece;Poland;Spain;Lithuania;Bulgaria;Germany;Italy | ||
| 15 | EUCTR2010-022206-40-BG (EUCTR) | 30/03/2011 | 24/02/2011 | A Rheumatoid Arthritis Study in Patients (FLEX-O) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX-O) | Rheumatoid Arthritis MedDRA version: 14.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1002 | Phase 3 | United States;Taiwan;Slovakia;Ukraine;Lithuania;Russian Federation;Colombia;Sri Lanka;India;Hungary;Mexico;Argentina;Malaysia;Poland;Croatia;Romania;Australia;Peru;Bulgaria;South Africa;Japan;New Zealand;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2010-022205-17-BG (EUCTR) | 29/03/2011 | 24/02/2011 | A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate (FLEX-M) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy (FLEX-M) | Rheumatoid Arthritis MedDRA version: 14.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 Trade Name: Boostrix® Product Name: Boostrix® Product Code: - Other descriptive name: DIPHTHERIA TOXOID Other descriptive name: TETANUS TOXOID Other descriptive name: PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE Other descriptive name: PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ADSORBED ON ALUMINIUM HYDROXIDE Other descriptive name: PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE Trade Name: PNEUMOVAX® 23 Product Name: PNEUMOVAX® 23 Product Code: - Other descriptive name: pneumococcal serotypes | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 990 | Phase 3 | United States;Taiwan;Slovakia;Ukraine;Lithuania;Russian Federation;Colombia;Sri Lanka;India;Hungary;Mexico;Argentina;Malaysia;Brazil;Poland;Croatia;Romania;Australia;Peru;Bulgaria;South Africa;Japan;New Zealand;Korea, Republic of | ||
| 17 | EUCTR2010-022208-36-BG (EUCTR) | 24/03/2011 | 24/02/2011 | An Open Label Study for Patients With Rheumatoid Arthritis (FLEX-P) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) (FLEX-P) | Rheumatoid Arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Other descriptive name: Not available Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Other descriptive name: Not available | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1505 | Phase 3b | United States;Taiwan;Slovakia;Greece;Spain;Ukraine;Russian Federation;Colombia;Sri Lanka;Italy;India;France;Malaysia;Peru;Australia;South Africa;Korea, Republic of;Lithuania;Hungary;Mexico;Argentina;Poland;Brazil;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan | ||
| 18 | EUCTR2010-022208-36-ES (EUCTR) | 21/03/2011 | 29/12/2010 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)Estudio en fase 3b, multicéntrico y abierto paraevaluar la seguridad y la eficacia a largo plazo deLY2127399 en pacientes con artritis reumatoide(AR) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA)Estudio en fase 3b, multicéntrico y abierto paraevaluar la seguridad y la eficacia a largo plazo deLY2127399 en pacientes con artritis reumatoide(AR) | Rheumatoid ArthritisArtritis Reumatoide MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1505 | Phase 3b | Hungary;Germany;Bulgaria;Spain;Greece;Poland;Lithuania | ||
| 19 | EUCTR2010-022207-22-ES (EUCTR) | 21/03/2011 | 29/12/2010 | A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacyand Safety of LY2127399 in Patients with Moderateto Severe Rheumatoid Arthritis (RA) who had anInadequate Response to one or more TNF-alphaInhibitorsEstudio de fase 3, multicéntrico, aleatorizado,doble ciego, controlado con placebo de evaluaciónde la eficacia y la seguridad de LY2127399 enpacientes con artritis reumatoide (AR) moderada ointensa que no han obtenido una respuestasuficiente con uno o varios inhibidores del TNF-alfa | A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacyand Safety of LY2127399 in Patients with Moderateto Severe Rheumatoid Arthritis (RA) who had anInadequate Response to one or more TNF-alphaInhibitorsEstudio de fase 3, multicéntrico, aleatorizado,doble ciego, controlado con placebo de evaluaciónde la eficacia y la seguridad de LY2127399 enpacientes con artritis reumatoide (AR) moderada ointensa que no han obtenido una respuestasuficiente con uno o varios inhibidores del TNF-alfa | Rheumatoid Arthritis Artritis Reumatoide MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 555 | Phase 3 | Greece;Poland;Spain;Germany;Italy | ||
| 20 | EUCTR2010-022207-22-GR (EUCTR) | 15/03/2011 | 20/01/2011 | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors | A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors | Rheumatoid Arthritis MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 555 | Phase 3 | Greece;Poland;Spain;Germany;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2010-022207-22-IT (EUCTR) | 24/02/2011 | 03/02/2011 | A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors - ND | A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a Inhibitors - ND | Rheumatoid Arthritis MedDRA version: 9.1;Level: PT;Classification code 10039073 | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 555 | Phase 3 | Greece;Poland;Spain;Germany;Italy | ||
| 22 | EUCTR2010-022206-40-HU (EUCTR) | 23/02/2011 | 26/11/2010 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy | Rheumatoid Arthritis MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1002 | Phase 3 | Hungary;Poland;Lithuania;Bulgaria | ||
| 23 | EUCTR2010-022205-17-HU (EUCTR) | 18/02/2011 | 15/12/2010 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to Methotrexate Therapy | Rheumatoid Arthritis MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 990 | Phase 3 | Hungary;Poland;Lithuania;Bulgaria | ||
| 24 | EUCTR2010-022208-36-HU (EUCTR) | 18/02/2011 | 26/11/2010 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) | Rheumatoid Arthritis MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1505 | Phase 3b | Hungary;Greece;Poland;Spain;Lithuania;Bulgaria;Germany;Italy | ||
| 25 | EUCTR2010-022208-36-IT (EUCTR) | 10/01/2011 | 08/02/2011 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis(RA) - ND | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis(RA) - ND | Rheumatoid Arthritis. MedDRA version: 9.1;Level: PT;Classification code 10039073 | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1505 | Phase 3b | Hungary;Greece;Poland;Spain;Lithuania;Bulgaria;Germany;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT01202773 (ClinicalTrials.gov) | January 2011 | 14/9/2010 | A Study in Participants With Rheumatoid Arthritis | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to One or More TNF-a Inhibitors (FLEX V) | Rheumatoid Arthritis | Drug: LY2127399;Drug: Placebo Q4W;Drug: Placebo Q2W | Eli Lilly and Company | NULL | Terminated | 18 Years | N/A | All | 456 | Phase 3 | United States;Argentina;Australia;Brazil;Colombia;France;Germany;Greece;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Russian Federation;South Africa;Spain;Taiwan |
| 27 | NCT01202760 (ClinicalTrials.gov) | January 2011 | 14/9/2010 | A Rheumatoid Arthritis Study in Participants | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX O) | Rheumatoid Arthritis | Drug: LY2127399;Drug: Placebo | Eli Lilly and Company | NULL | Completed | 18 Years | N/A | All | 1004 | Phase 3 | United States;Argentina;Australia;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;Peru |
| 28 | EUCTR2010-022206-40-SK (EUCTR) | 13/12/2010 | 27/04/2016 | A Rheumatoid Arthritis Study in Patients (FLEX-O) | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy (FLEX-O) | Rheumatoid Arthritis MedDRA version: 19.0;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Product Name: LY2127399 Product Code: LY2127399 Product Name: LY2127399 Product Code: LY2127399 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1002 | Phase 3 | United States;Taiwan;Slovakia;Ukraine;Lithuania;Russian Federation;Colombia;Sri Lanka;India;Hungary;Mexico;Argentina;Poland;Malaysia;Romania;Croatia;Peru;Australia;South Africa;Bulgaria;New Zealand;Japan;Korea, Republic of | ||
| 29 | NCT01198002 (ClinicalTrials.gov) | December 2010 | 8/9/2010 | A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients With Moderate to Severe Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate Therapy (FLEX M) | Rheumatoid Arthritis | Drug: LY2127399;Drug: Placebo Q2W;Drug: Placebo Q4W;Drug: Methotrexate | Eli Lilly and Company | NULL | Terminated | 18 Years | N/A | All | 1041 | Phase 3 | United States;Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;Peru |
| 30 | NCT01253291 (ClinicalTrials.gov) | May 2010 | 1/12/2010 | A Study of Japanese Rheumatoid Arthritis Participants | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate | Rheumatoid Arthritis | Drug: LY2127399 | Eli Lilly and Company | NULL | Completed | 20 Years | 75 Years | All | 26 | Phase 1 | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2008-004894-16-HU (EUCTR) | 03/12/2009 | 17/11/2008 | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | Hungary;Czech Republic;Germany;Poland | ||
| 32 | NCT01253226 (ClinicalTrials.gov) | September 2009 | 1/12/2010 | A Study for Japanese Participants With Rheumatoid Arthritis (RA) | Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate | Rheumatoid Arthritis | Drug: LY2127399 (Tabalumab);Drug: Placebo | Eli Lilly and Company | NULL | Completed | 20 Years | 75 Years | All | 32 | Phase 1 | Japan |
| 33 | EUCTR2008-004875-23-HU (EUCTR) | 08/07/2009 | 11/05/2009 | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 198 | Hungary;Germany;Belgium;France;Austria;Poland | |||
| 34 | EUCTR2008-004875-23-AT (EUCTR) | 26/06/2009 | 30/04/2009 | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: NA Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 236 | Hungary;Germany;Belgium;France;Poland;Austria | |||
| 35 | EUCTR2008-001105-42-PL (EUCTR) | 03/06/2009 | 17/04/2009 | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Code: LY2127399 INN or Proposed INN: N/A Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Germany;Belgium;France;Austria;Poland | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2008-004875-23-DE (EUCTR) | 26/05/2009 | 09/03/2009 | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: NA Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 236 | Hungary;Germany;Belgium;France;Austria;Poland | |||
| 37 | EUCTR2008-004875-23-BE (EUCTR) | 18/05/2009 | 07/01/2009 | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 236 | France;Hungary;Poland;Belgium;Austria;Germany | |||
| 38 | EUCTR2008-004875-23-PL (EUCTR) | 22/04/2009 | 25/02/2009 | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Product Code: NA Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 236 | Hungary;Germany;Belgium;France;Austria;Poland | |||
| 39 | EUCTR2008-004894-16-CZ (EUCTR) | 14/04/2009 | 26/11/2008 | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company limited | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Hungary;Germany;Czech Republic;Poland | ||
| 40 | EUCTR2008-004875-23-FR (EUCTR) | 31/03/2009 | 16/04/2009 | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 236 | Hungary;Germany;Belgium;France;Austria;Poland | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2008-004894-16-DE (EUCTR) | 12/02/2009 | 11/11/2008 | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company limited | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Hungary;Czech Republic;Germany;Poland | ||
| 42 | NCT00837811 (ClinicalTrials.gov) | February 2009 | 3/2/2009 | An Open Label Extension Study in Participants With Rheumatoid Arthritis | An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis. | Rheumatoid Arthritis | Biological: LY2127399 | Eli Lilly and Company | NULL | Completed | 18 Years | N/A | All | 182 | Phase 2 | United States;Australia;Austria;Belgium;Brazil;Canada;Chile;Germany;Hungary;India;Mexico;Poland;Puerto Rico;Romania;Argentina;Czech Republic;France;Slovakia;Ukraine |
| 43 | EUCTR2008-004894-16-PL (EUCTR) | 15/01/2009 | 18/12/2008 | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: LY2127399 Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company limited | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 2 | Hungary;Czech Republic;Germany;Poland | ||
| 44 | EUCTR2008-001105-42-AT (EUCTR) | 11/11/2008 | 06/08/2008 | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: NA Product Code: LY2127399 INN or Proposed INN: N/A Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Germany;Belgium;France;Poland;Austria | ||
| 45 | EUCTR2008-001105-42-DE (EUCTR) | 16/10/2008 | 04/08/2008 | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Code: LY2127399 INN or Proposed INN: N/A Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Germany;Belgium;France;Poland;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | EUCTR2008-001105-42-FR (EUCTR) | 10/10/2008 | 28/08/2008 | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Code: LY2127399 INN or Proposed INN: N/A Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | Germany;Belgium;France;Poland;Austria | ||
| 47 | NCT00785928 (ClinicalTrials.gov) | October 2008 | 3/11/2008 | A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy | Rheumatoid Arthritis | Biological: LY2127399;Drug: Placebo | Eli Lilly and Company | NULL | Completed | 18 Years | 75 Years | All | 158 | Phase 2 | United States;Argentina;Australia;Chile;Germany;Hungary;India;Mexico;Poland;Romania;Slovakia;Ukraine;Brazil;Canada;Czech Republic |
| 48 | EUCTR2008-001105-42-BE (EUCTR) | 16/09/2008 | 14/07/2008 | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | A Phase 2 Study of Multiple Intravenous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy - BCDG | Rheumatoid arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Code: LY2127399 INN or Proposed INN: N/A Other descriptive name: Anti LP40 antibody, subclass IgG4 LA294 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | France;Poland;Belgium;Austria;Germany | ||
| 49 | NCT00689728 (ClinicalTrials.gov) | June 2008 | 2/6/2008 | A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFa Inhibitor Therapy | A Phase 2 Study of Multiple Intravenous Doses of LY2127399 in Patients With Rheumatoid Arthritis on Concomitant Methotrexate and an Inadequate Response to TNFa Inhibitor Therapy | Arthritis, Rheumatoid | Biological: LY2127399;Drug: Placebo | Eli Lilly and Company | NULL | Completed | 18 Years | 75 Years | All | 100 | Phase 2 | United States;Argentina;Austria;Belgium;Brazil;Canada;Germany;Mexico;Poland;Puerto Rico;France |
| 50 | NCT00308282 (ClinicalTrials.gov) | March 28, 2006 | 28/3/2006 | A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis | Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate | Arthritis, Rheumatoid | Drug: LY2127399;Drug: Placebo | Eli Lilly and Company | NULL | Completed | 18 Years | 75 Years | All | 136 | Phase 2 | Romania |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-022101-18-HR (EUCTR) | 31/03/2014 | 17/10/2014 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 17.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan | ||
| 2 | NCT02041091 (ClinicalTrials.gov) | January 2014 | 17/1/2014 | A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus | Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic | Drug: Tabalumab Auto-Injector;Drug: Tabalumab Prefilled Syringe | Eli Lilly and Company | NULL | Terminated | 18 Years | N/A | All | 226 | Phase 3 | United States;Korea, Republic of;Puerto Rico;Mexico |
| 3 | EUCTR2010-022101-18-IT (EUCTR) | 13/05/2013 | 03/09/2012 | Non disponibile | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 15.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 | ELI LILLY AND COMPANY | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | United States;Belarus;Philippines;Taiwan;Ecuador;Spain;Thailand;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Brazil;Singapore;Croatia;Bulgaria;Germany;Japan;New Zealand | ||
| 4 | EUCTR2010-022101-18-DE (EUCTR) | 20/03/2013 | 10/12/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | United States;Belarus;Serbia;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Australia;Peru;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Singapore;Romania;Croatia;Bulgaria;Germany;Japan;New Zealand | ||
| 5 | EUCTR2010-022101-18-GB (EUCTR) | 21/12/2012 | 28/11/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 INN or Proposed INN: Not available Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | United States;Belarus;Serbia;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Australia;Peru;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Brazil;Poland;Singapore;Romania;Croatia;Bulgaria;Germany;Japan;New Zealand | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2010-022101-18-BG (EUCTR) | 28/08/2012 | 29/08/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 17.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Russian Federation;Israel;Chile;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan | ||
| 7 | EUCTR2010-022101-18-HU (EUCTR) | 17/08/2012 | 17/05/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Croatia;Romania;Bulgaria;Germany;Japan;New Zealand;Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia | ||
| 8 | EUCTR2010-022101-18-LV (EUCTR) | 10/08/2012 | 28/05/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Chile;Russian Federation;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Croatia;Romania;Bulgaria;Germany;Japan;New Zealand | ||
| 9 | EUCTR2010-022101-18-ES (EUCTR) | 25/05/2012 | 21/05/2012 | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 14.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | Serbia;United States;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Israel;Russian Federation;Chile;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Latvia;Tunisia;Korea, Democratic People's Republic of;Guatemala;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Croatia;Romania;Bulgaria;Germany;Japan;New Zealand | ||
| 10 | EUCTR2010-022101-18-AT (EUCTR) | 14/05/2012 | 11/04/2012 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-X) - ILLUMINATE-X | Systemic Lupus Erythematosus (SLE) MedDRA version: 14.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4; Anti BAFF (B cell activating factor) | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1276 | Phase 3b | United States;Serbia;Belarus;Philippines;Taiwan;Ecuador;Thailand;Spain;Ukraine;Russian Federation;Chile;Israel;Colombia;Italy;India;France;Macedonia, the former Yugoslav Republic of;Malaysia;Peru;Australia;South Africa;Tunisia;Latvia;Guatemala;Korea, Democratic People's Republic of;Turkey;Austria;United Kingdom;Egypt;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Singapore;Romania;Croatia;Bulgaria;Germany;New Zealand;Japan | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01488708 (ClinicalTrials.gov) | January 2012 | 6/12/2011 | On Open-Label Study in Participants With Systemic Lupus Erythematosus | A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X) | Systemic Lupus Erythematosus;Connective Tissue Disease;Autoimmune Disease | Drug: LY2127399;Drug: Placebo | Eli Lilly and Company | NULL | Terminated | 18 Years | N/A | All | 1518 | Phase 3 | United States |
| 12 | EUCTR2010-022099-29-DE (EUCTR) | 04/07/2011 | 14/12/2010 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-1) - ILLUMINATE-1 | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | United States;Belarus;Philippines;Thailand;Ukraine;Guatemala;Turkey;Austria;Chile;Colombia;Italy;Egypt;Canada;Macedonia, the former Yugoslav Republic of;Argentina;Poland;Singapore;Croatia;Peru;Bulgaria;Germany;Japan;Korea, Republic of | ||
| 13 | EUCTR2010-022099-29-BG (EUCTR) | 16/06/2011 | 24/02/2011 | Study investigating a new medicine, LY2127399, in patients diagnosed with Systemic Lupus Erythematosus (SLE). | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-1) - ILLUMINATE-1 | Systemic Lupus Erythematosus (SLE) MedDRA version: 17.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | United States;Belarus;Philippines;Thailand;Guatemala;Ukraine;Turkey;Austria;Chile;Colombia;Italy;Egypt;Macedonia, the former Yugoslav Republic of;Canada;Argentina;Poland;Singapore;Croatia;Peru;Bulgaria;Germany;Japan;Korea, Republic of | ||
| 14 | EUCTR2010-022099-29-IT (EUCTR) | 01/06/2011 | 07/02/2011 | A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) - ND | A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) - ND | Systemic Lupus Erythematosus (SLE) MedDRA version: 9.1;Level: PT;Classification code 10042945 | Product Name: LY2127399 Product Code: LY2127399 | ELI LILLY | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | Austria;Bulgaria;Germany;Italy | ||
| 15 | EUCTR2010-022100-42-GB (EUCTR) | 28/04/2011 | 19/01/2011 | Not available | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2) - (ILLUMINATE-2) | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | United States;Serbia;Taiwan;Ecuador;Spain;Russian Federation;Israel;United Kingdom;India;France;Hungary;Mexico;Canada;Brazil;Malaysia;Romania;Australia;South Africa;Tunisia;Latvia;New Zealand | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2010-022100-42-ES (EUCTR) | 20/04/2011 | 15/02/2011 | Estudio de Fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de LY2127399 subcutáneo en pacientes con lupus sistémico eritematoso (LSE)//A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacy andSafety of Subcutaneous LY2127399 in Patients withSystemic Lupus Erythematosus (SLE) | Estudio de Fase 3, multicéntrico, aleatorizado, doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de LY2127399 subcutáneo en pacientes con lupus sistémico eritematoso (LSE)//A Phase 3, Multicenter, Randomized, Double-Blind,Placebo-Controlled Study to Evaluate the Efficacy andSafety of Subcutaneous LY2127399 in Patients withSystemic Lupus Erythematosus (SLE) | Lupus Eritematoso Sistémico (LES) //Systemic Lupus Erythematosus (SLE) MedDRA version: 12.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: Anti LP40 anticuerpo, subclase IgG4 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | Hungary;Spain;Latvia;United Kingdom | ||
| 17 | EUCTR2010-022100-42-LV (EUCTR) | 08/04/2011 | 13/01/2011 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2) - ILLUMINATE-2 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2) - ILLUMINATE-2 | Systemic Lupus Erythematosus (SLE) MedDRA version: 16.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | Serbia;United States;Taiwan;Ecuador;Spain;Israel;Russian Federation;United Kingdom;India;France;Hungary;Mexico;Canada;Malaysia;Brazil;Romania;Australia;South Africa;Latvia;Tunisia;New Zealand | ||
| 18 | EUCTR2010-022100-42-HU (EUCTR) | 23/02/2011 | 13/01/2011 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2) - ILLUMINATE-2 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2) - ILLUMINATE-2 | Systemic Lupus Erythematosus (SLE) MedDRA version: 14.1;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | Serbia;United States;Taiwan;Ecuador;Spain;Israel;Russian Federation;United Kingdom;India;France;Hungary;Mexico;Canada;Malaysia;Brazil;Romania;Australia;South Africa;Latvia;Tunisia;New Zealand | ||
| 19 | EUCTR2010-022099-29-AT (EUCTR) | 27/01/2011 | 28/12/2010 | Study investigating a new medicine, LY2127399, in patients diagnosedwith Systemic Lupus Erythematosus (SLE). | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-1) - ILLUMINATE-1 | Systemic Lupus Erythematosus (SLE) MedDRA version: 17.0;Level: LLT;Classification code 10025139;Term: Lupus erythematosus systemic;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: LY2127399 Product Code: LY2127399 Other descriptive name: LA294; Anti LP40 antibody, subclass IgG4 | Eli Lilly and Company | NULL | Not Recruiting | Female: yes Male: yes | 1140 | Phase 3 | United States;Belarus;Philippines;Thailand;Ukraine;Guatemala;Turkey;Austria;Chile;Colombia;Italy;Egypt;Macedonia, the former Yugoslav Republic of;Canada;Argentina;Poland;Singapore;Croatia;Peru;Bulgaria;Germany;Japan;Korea, Republic of | ||
| 20 | NCT01205438 (ClinicalTrials.gov) | January 2011 | 17/9/2010 | A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus;Connective Tissue Disease;Autoimmune Disease | Drug: LY2127399;Drug: Placebo every 2 weeks;Drug: Placebo every 4 weeks | Eli Lilly and Company | NULL | Completed | 18 Years | N/A | All | 1124 | Phase 3 | United States;Australia;Brazil;Canada;Ecuador;France;Hungary;India;Israel;Latvia;Malaysia;Mexico;New Zealand;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Tunisia;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT01196091 (ClinicalTrials.gov) | December 2010 | 3/9/2010 | A Study of LY2127399 in Participants With Systemic Lupus Erythematosus | A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) | Systemic Lupus Erythematosus;Connective Tissue Disease;Autoimmune Disease | Drug: LY2127399;Drug: Placebo every 2 weeks;Drug: Placebo every 4 weeks;Drug: Standard of Care | Eli Lilly and Company | NULL | Completed | 18 Years | N/A | All | 1164 | Phase 3 | United States;Argentina;Austria;Belarus;Bulgaria;Canada;Chile;Colombia;Croatia;Egypt;Germany;Guatemala;Italy;Japan;Korea, Republic of;Macedonia, The Former Yugoslav Republic of;Peru;Philippines;Poland;Puerto Rico;Singapore;Thailand;Ukraine;Turkey |